Oramed (NASDAQ: ORMP) CEO receives 109,000 shares from PSU vesting

Rhea-AI Filing Summary

Oramed Pharmaceuticals Inc. insider filing: President and CEO Nadav Kidron reported the vesting of performance stock units tied to Oramed’s share price. On January 22, 2026, 109,000 PSUs converted into 109,000 shares of common stock for no cash consideration.

Each PSU gave the right to receive one share when specific performance criteria were met. Following this vesting, Kidron directly owns 3,355,238 shares of Oramed common stock.

Insider Trade Summary

109,000 shares exercised/converted

Mixed 2 txns

Insider KIDRON NADAV

Role President and CEO

Type	Security	Shares	Price	Value
Exercise	Performance Stock Units	109,000	$0.00	--
Exercise	Common Stock	109,000	$0.00	--

Holdings After Transaction: Performance Stock Units — 0 shares (Direct); Common Stock — 3,355,238 shares (Direct)

Footnotes (1)

1. Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIDRON NADAV

(Last) (First) (Middle)

1185 AVENUE OF THE AMERICAS

THIRD FLOOR

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		M		109,000(1)	A	$0(1)	3,355,238	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	01/22/2026		M			109,000	(2)	(2)	Common Stock	109,000	$0	0	D

Explanation of Responses:

1. Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

2. Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

	/s/ Nadav Kidron	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ORMP CEO Nadav Kidron report on this Form 4?

Nadav Kidron reported the vesting of 109,000 performance stock units into common shares. The PSUs vested when Oramed’s stock reached specified price conditions, resulting in him receiving 109,000 shares without paying cash consideration.

How many Oramed (ORMP) shares does Nadav Kidron own after this transaction?

After the PSU vesting, Nadav Kidron directly owns 3,355,238 shares of Oramed common stock. This figure reflects his beneficial ownership immediately following conversion of 109,000 performance stock units into an equal number of common shares.

What triggered the vesting of Nadav Kidron’s performance stock units at Oramed (ORMP)?

The performance stock units vested when Oramed’s common stock achieved a specified price per share. The PSUs, granted on December 31, 2025, converted into common shares on January 22, 2026 once the defined performance criteria were satisfied.

Did Nadav Kidron pay anything for the 109,000 Oramed (ORMP) shares received?

No, Nadav Kidron did not pay cash for the 109,000 shares. The filing states the common shares were received for no consideration when the previously granted performance stock units vested upon achieving the required stock price performance.

What are performance stock units (PSUs) in the Oramed (ORMP) Form 4 filing?

In this filing, each performance stock unit represents a right to receive one Oramed common share. The PSUs granted to Nadav Kidron converted into 109,000 shares once specified performance criteria, including a stock price condition, were met on January 22, 2026.